U.S. markets closed
  • S&P Futures

    3,767.50
    -22.00 (-0.58%)
     
  • Dow Futures

    30,598.00
    -183.00 (-0.59%)
     
  • Nasdaq Futures

    11,461.75
    -67.75 (-0.59%)
     
  • Russell 2000 Futures

    1,692.90
    -15.10 (-0.88%)
     
  • Crude Oil

    106.01
    +0.25 (+0.24%)
     
  • Gold

    1,805.60
    -1.70 (-0.09%)
     
  • Silver

    20.15
    -0.20 (-0.99%)
     
  • EUR/USD

    1.0469
    -0.0014 (-0.14%)
     
  • 10-Yr Bond

    2.9720
    -0.1210 (-3.91%)
     
  • Vix

    28.71
    +0.55 (+1.95%)
     
  • GBP/USD

    1.2144
    -0.0031 (-0.25%)
     
  • USD/JPY

    135.2670
    -0.4610 (-0.34%)
     
  • BTC-USD

    20,297.75
    +231.23 (+1.15%)
     
  • CMC Crypto 200

    434.50
    +3.04 (+0.70%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    26,159.53
    -233.51 (-0.88%)
     

Bio-Rad Laboratories: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 72.84% year over year to $4.01, which beat the estimate of $3.29.

Revenue of $789,839,000 up by 26.49% from the same period last year, which beat the estimate of $686,800,000.

Looking Ahead

Bio-Rad Sees FY21 Adj. Currency-Neutral Sales Growth 4.5-5% Year Over Year

Details Of The Call

Date: Feb 11, 2021

Time: 06:00 PM

View more earnings on BIO

ET Webcast URL: https://edge.media-server.com/mmc/p/8cfv55c7

Technicals

52-week high: $648.39

Company's 52-week low was at $309.38

Price action over last quarter: Up 9.79%

Company Overview

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2019 sales), Europe (33%), and Asia (22%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.